At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCYX SCYNEXIS Inc
Post-Mkt 12-22 17:05:11 EST
0.6125
-0.0145
-2.31%
盘后0.6113
-0.0012-0.20%
16:04 EST
High0.6325Low0.6113Vol237.94K
Open0.6211D1 Closing0.6270Amplitude3.38%
Mkt Cap25.70MTradable Cap23.01MTotal Shares41.97M
T/O148.18KT/O Rate0.63%Tradable Shares37.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

SCYNEXIS Granted Nasdaq Extension to Regain Minimum Bid Price Compliance
Reuters  ·  12-22 21:03
SCYNEXIS Granted Nasdaq Extension to Regain Minimum Bid Price Compliance
Scynexis Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Requirement
THOMSON REUTERS  ·  12-22 21:00
Scynexis Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Requirement
Scynexis Transfers Brexafemme New Drug Application to GSK
MT Newswires Live  ·  11-19
Scynexis Transfers Brexafemme New Drug Application to GSK
Scynexis Inc - to Receive up to $145.5 Mln in Annual Net Sales Milestones as Well as Royalties
THOMSON REUTERS  ·  11-19
Scynexis Inc - to Receive up to $145.5 Mln in Annual Net Sales Milestones as Well as Royalties
Scynexis Completes Transfer of Brexafemme® New Drug Application to GSK
THOMSON REUTERS  ·  11-19
Scynexis Completes Transfer of Brexafemme® New Drug Application to GSK
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
GlobeNewswire  ·  11-19
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
TIPRANKS  ·  11-17
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
SCYNEXIS and Partners Secure $7 Million Annual NIH Grant for Novel Antifungal Development
Reuters  ·  11-17
SCYNEXIS and Partners Secure $7 Million Annual NIH Grant for Novel Antifungal Development
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
GlobeNewswire  ·  11-17
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
SCYNEXIS Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-07
SCYNEXIS Inc reports results for the quarter ended September 30 - Earnings Summary
Antifungal drug developer Scynexis's Q3 net loss widens
Reuters  ·  11-06
Antifungal drug developer Scynexis's Q3 net loss widens
BRIEF-Scynexis Q3 Pretax Profit USD -8.591 Million
Reuters  ·  11-06
BRIEF-Scynexis Q3 Pretax Profit USD -8.591 Million
Scynexis Q3 Basic EPS USD -0.17
THOMSON REUTERS  ·  11-06
Scynexis Q3 Basic EPS USD -0.17
SCYNEXIS Inc expected to post a loss of 20 cents a share - Earnings Preview
Reuters  ·  11-01
SCYNEXIS Inc expected to post a loss of 20 cents a share - Earnings Preview
Scynexis Is Maintained at Buy by Guggenheim
Dow Jones  ·  10-28
Scynexis Is Maintained at Buy by Guggenheim
Scynexis to Receive $22 Million Resolving Disagreement With GSK Over Phase 3 Mario Study; Shares Rise Pre-Bell
MT Newswires Live  ·  10-15
Scynexis to Receive $22 Million Resolving Disagreement With GSK Over Phase 3 Mario Study; Shares Rise Pre-Bell
GSK to Pay Scynexis $22 Million to Resolve Disagreement Over Fungal Infection Treatment Study
Dow Jones  ·  10-15
GSK to Pay Scynexis $22 Million to Resolve Disagreement Over Fungal Infection Treatment Study
BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study
Reuters  ·  10-15
BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study
SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments
Reuters  ·  10-15
SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments
Scynexis Inc - to Receive Additional $2.3 Mln for Wind-Down Activities
THOMSON REUTERS  ·  10-15
Scynexis Inc - to Receive Additional $2.3 Mln for Wind-Down Activities

Introduction

Company Name.
SCYNEXIS Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Issue price:
--